Magle Chemoswed (MAGLE) Q4 2024 earnings summary

Executive summary

• Achieved strong organic growth in DSM and CDMO segments, supported by successful integration of PK Chemical and Amniotics acquisitions.

• Expanded into dextran-based biopolymers and amniotic MSCs, reinforcing innovation pipeline.

• Strategic investments in 2024 aimed at long-term efficiency and profitability.

Financial highlights

• Q4 2024 revenue was 84.1 MSEK, up from 59.5 MSEK year-over-year; full-year revenue reached 256.1 MSEK, up from 183.1 MSEK.

• Q4 EBITDA rose to 20.1 MSEK (9.3 MSEK last year); full-year EBITDA was 58.9 MSEK (31.1 MSEK prior year).

• Q4 EBIT was 4.0 MSEK (5.9 MSEK last year); full-year EBIT was 23.2 MSEK (18.0 MSEK prior year).

• Q4 net loss of -0.8 MSEK (net profit 4.1 MSEK last year); full-year net profit 11.9 MSEK (12.2 MSEK prior year).

• Earnings per share for Q4 was -0.04 SEK (0.38 SEK last year); full-year EPS was 0.93 SEK (1.13 SEK prior year).

Outlook and guidance

• Investments in 2024 expected to drive future efficiency gains and sustained profitability.

• Focus remains on organic expansion, strategic acquisitions, and technological innovation to maintain competitiveness.